Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Basmisanil, a highly selective GABAA-α5 negative allosteric modulator: preclinical pharmacology and demonstration of functional target engagement in man.
Hipp JF
,
Knoflach F
,
Comley R
,
Ballard TM
,
Honer M
,
Trube G
,
Gasser R
,
Prinssen E
,
Wallace TL
,
Rothfuss A
,
Knust H
,
Lennon-Chrimes S
,
Derks M
,
Bentley D
,
Squassante L
,
Nave S
,
Nöldeke J
,
Wandel C
,
Thomas AW
,
Hernandez MC
.
???displayArticle.abstract??? GABAA-α5 subunit-containing receptors have been shown to play a key modulatory role in cognition and represent a promising drug target for cognitive dysfunction, as well as other disorders. Here we report on the preclinical and early clinical profile of a novel GABAA-α5 selective negative allosteric modulator (NAM), basmisanil, which progressed into Phase II trials for intellectual disability in Down syndrome and cognitive impairment associated with schizophrenia. Preclinical pharmacology studies showed that basmisanil is the most selective GABAA-α5 receptor NAM described so far. Basmisanil bound to recombinant human GABAA-α5 receptors with 5 nM affinity and more than 90-fold selectivity versus α1, α2, and α3 subunit-containing receptors. Moreover, basmisanil inhibited GABA-induced currents at GABAA-α5 yet had little or no effect at the other receptor subtypes. An in vivo occupancy study in rats showed dose-dependent target engagement and was utilized to establish the plasma exposure to receptor occupancy relationship. At estimated receptor occupancies between 30 and 65% basmisanil attenuated diazepam-induced spatial learning impairment in rats (Morris water maze), improved executive function in non-human primates (object retrieval), without showing anxiogenic or proconvulsant effects in rats. During the Phase I open-label studies, basmisanil showed good safety and tolerability in healthy volunteers at maximum GABAA-α5 receptor occupancy as confirmed by PET analysis with the tracer [11C]-Ro 15-4513. An exploratory EEG study provided evidence for functional activity of basmisanil in human brain. Therefore, these preclinical and early clinical studies show that basmisanil has an ideal profile to investigate potential clinical benefits of GABAA-α5 receptor negative modulation.
Atack,
In vitro and in vivo properties of 3-tert-butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy)-pyrazolo[1,5-d]-[1,2,4]triazine (MRK-016), a GABAA receptor alpha5 subtype-selective inverse agonist.
2009, Pubmed
Atack,
In vitro and in vivo properties of 3-tert-butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy)-pyrazolo[1,5-d]-[1,2,4]triazine (MRK-016), a GABAA receptor alpha5 subtype-selective inverse agonist.
2009,
Pubmed
Atack,
Preclinical and clinical pharmacology of the GABAA receptor alpha5 subtype-selective inverse agonist alpha5IA.
2010,
Pubmed
Atack,
The plasma-occupancy relationship of the novel GABAA receptor benzodiazepine site ligand, alpha5IA, is similar in rats and primates.
2009,
Pubmed
Atack,
L-655,708 enhances cognition in rats but is not proconvulsant at a dose selective for alpha5-containing GABAA receptors.
2006,
Pubmed
Ballard,
RO4938581, a novel cognitive enhancer acting at GABAA alpha5 subunit-containing receptors.
2009,
Pubmed
Ballard,
The effect of the mGlu5 receptor antagonist MPEP in rodent tests of anxiety and cognition: a comparison.
2005,
Pubmed
Braudeau,
Specific targeting of the GABA-A receptor α5 subtype by a selective inverse agonist restores cognitive deficits in Down syndrome mice.
2011,
Pubmed
Bundgaard,
RO4938581, a GABAAα5 modulator, displays strong CYP1A2 autoinduction properties in rats.
2013,
Pubmed
Buzsáki,
Neuronal oscillations in cortical networks.
2004,
Pubmed
Casula,
Identification of amino acid residues responsible for the alpha5 subunit binding selectivity of L-655,708, a benzodiazepine binding site ligand at the GABA(A) receptor.
2001,
Pubmed
,
Xenbase
Chen,
GABAA receptor-associated protein regulates GABAA receptor cell-surface number in Xenopus laevis oocytes.
2005,
Pubmed
,
Xenbase
Clarkson,
Reducing excessive GABA-mediated tonic inhibition promotes functional recovery after stroke.
2010,
Pubmed
Dawson,
An inverse agonist selective for alpha5 subunit-containing GABAA receptors enhances cognition.
2006,
Pubmed
,
Xenbase
Dorow,
Severe anxiety induced by FG 7142, a beta-carboline ligand for benzodiazepine receptors.
1983,
Pubmed
Duka,
The effects of a benzodiazepine receptor antagonist beta-carboline ZK-93426 on scopolamine-induced impairment on attention, memory and psychomotor skills.
1996,
Pubmed
Fischell,
Rapid Antidepressant Action and Restoration of Excitatory Synaptic Strength After Chronic Stress by Negative Modulators of Alpha5-Containing GABAA Receptors.
2015,
Pubmed
Friedman,
Pharmacokinetics and pharmacodynamics of oral diazepam: effect of dose, plasma concentration, and time.
1992,
Pubmed
Fritschy,
GABAA-receptor alpha-subunit is an essential prerequisite for receptor formation in vivo.
1997,
Pubmed
Frohlich,
Electrophysiological Phenotype in Angelman Syndrome Differs Between Genotypes.
2019,
Pubmed
Frohlich,
Mechanisms underlying the EEG biomarker in Dup15q syndrome.
2019,
Pubmed
Grabner,
Symmetric atlasing and model based segmentation: an application to the hippocampus in older adults.
2006,
Pubmed
Gunn,
Parametric imaging of ligand-receptor binding in PET using a simplified reference region model.
1997,
Pubmed
Hadingham,
Cloning of cDNA sequences encoding human alpha 2 and alpha 3 gamma-aminobutyric acidA receptor subunits and characterization of the benzodiazepine pharmacology of recombinant alpha 1-, alpha 2-, alpha 3-, and alpha 5-containing human gamma-aminobutyric acidA receptors.
1993,
Pubmed
Halldin,
[11C]Ro 15-4513, a ligand for visualization of benzodiazepine receptor binding. Preparation, autoradiography and positron emission tomography.
1992,
Pubmed
Hipp,
Dissociating neuronal gamma-band activity from cranial and ocular muscle activity in EEG.
2013,
Pubmed
Kawaharada,
ONO-8590580, a Novel GABAAα5 Negative Allosteric Modulator Enhances Long-Term Potentiation and Improves Cognitive Deficits in Preclinical Models.
2018,
Pubmed
Lake,
The effects of delayed reduction of tonic inhibition on ischemic lesion and sensorimotor function.
2015,
Pubmed
Lammertsma,
Simplified reference tissue model for PET receptor studies.
1996,
Pubmed
Li,
Evaluation of native GABA(A) receptors containing an alpha 5 subunit.
2001,
Pubmed
Little,
Acute and chronic effects of the benzodiazepine receptor ligand FG 7142: proconvulsant properties and kindling.
1984,
Pubmed
Löscher,
Preclinical assessment of proconvulsant drug activity and its relevance for predicting adverse events in humans.
2009,
Pubmed
Maeda,
Visualization of alpha5 subunit of GABAA/benzodiazepine receptor by 11C Ro15-4513 using positron emission tomography.
2003,
Pubmed
Malherbe,
Me-talnetant and osanetant interact within overlapping but not identical binding pockets in the human tachykinin neurokinin 3 receptor transmembrane domains.
2008,
Pubmed
Malizia,
Benzodiazepine site pharmacokinetic/pharmacodynamic quantification in man: direct measurement of drug occupancy and effects on the human brain in vivo.
1996,
Pubmed
Martínez-Cué,
Reducing GABAA α5 receptor-mediated inhibition rescues functional and neuromorphological deficits in a mouse model of down syndrome.
2013,
Pubmed
Maubach,
GABA(A) receptor subtype selective cognition enhancers.
2003,
Pubmed
McGinnity,
Test-retest reproducibility of quantitative binding measures of [11C]Ro15-4513, a PET ligand for GABAA receptors containing alpha5 subunits.
2017,
Pubmed
McKernan,
GABAA receptor subtypes immunopurified from rat brain with alpha subunit-specific antibodies have unique pharmacological properties.
1991,
Pubmed
McNaughton,
Chlordiazepoxide, an anxiolytic benzodiazepine, impairs place navigation in rats.
1987,
Pubmed
Merschman,
Characterization of the solubility of a poorly soluble hydroxylated metabolite in human urine and its implications for potential renal toxicity.
2005,
Pubmed
Morris,
Developments of a water-maze procedure for studying spatial learning in the rat.
1984,
Pubmed
Myers,
Quantification of [11C]Ro15-4513 GABAAα5 specific binding and regional selectivity in humans.
2017,
Pubmed
Nichols,
Nonparametric permutation tests for functional neuroimaging: a primer with examples.
2002,
Pubmed
Nicolas,
Social approach-avoidance behavior of a high-anxiety strain of rats: effects of benzodiazepine receptor ligands.
2006,
Pubmed
Nutt,
Blockade of alcohol's amnestic activity in humans by an alpha5 subtype benzodiazepine receptor inverse agonist.
2007,
Pubmed
Olsen,
GABA A receptors: subtypes provide diversity of function and pharmacology.
2009,
Pubmed
Percie du Sert,
The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research.
2020,
Pubmed
Petersen,
THIP: a single-blind controlled trial in patients with epilepsy.
1983,
Pubmed
Pirker,
GABA(A) receptors: immunocytochemical distribution of 13 subunits in the adult rat brain.
2000,
Pubmed
Porjesz,
Linkage disequilibrium between the beta frequency of the human EEG and a GABAA receptor gene locus.
2002,
Pubmed
Povroznik,
Effects of an α5GABAA inverse agonist on MK-801-induced learning deficits in an incremental repeated acquisition task.
2014,
Pubmed
Quirk,
[3H]L-655,708, a novel ligand selective for the benzodiazepine site of GABAA receptors which contain the alpha 5 subunit.
1996,
Pubmed
Redrobe,
Negative modulation of GABAA α5 receptors by RO4938581 attenuates discrete sub-chronic and early postnatal phencyclidine (PCP)-induced cognitive deficits in rats.
2012,
Pubmed
,
Xenbase
Rudolph,
Beyond classical benzodiazepines: novel therapeutic potential of GABAA receptor subtypes.
2011,
Pubmed
Rutten,
Selective PDE inhibitors rolipram and sildenafil improve object retrieval performance in adult cynomolgus macaques.
2008,
Pubmed
Savić,
PWZ-029, a compound with moderate inverse agonist functional selectivity at GABA(A) receptors containing alpha5 subunits, improves passive, but not active, avoidance learning in rats.
2008,
Pubmed
,
Xenbase
Schmidt,
Age dependence of excitatory-inhibitory balance following stroke.
2012,
Pubmed
Sieghart,
International Union of Basic and Clinical Pharmacology. CVI: GABAA Receptor Subtype- and Function-selective Ligands: Key Issues in Translation to Humans.
2018,
Pubmed
Sieghart,
Structure and pharmacology of gamma-aminobutyric acidA receptor subtypes.
1995,
Pubmed
Sigel,
Structure, function, and modulation of GABA(A) receptors.
2012,
Pubmed
Smit,
Genome-wide association analysis links multiple psychiatric liability genes to oscillatory brain activity.
2018,
Pubmed
Smith,
Advances in functional and structural MR image analysis and implementation as FSL.
2004,
Pubmed
Stillhart,
Characterising Drug Release from Immediate-Release Formulations of a Poorly Soluble Compound, Basmisanil, Through Absorption Modelling and Dissolution Testing.
2017,
Pubmed
Sur,
Autoradiographic localization of alpha5 subunit-containing GABAA receptors in rat brain.
1999,
Pubmed
Timić Stamenić,
Negative modulation of α₅ GABAA receptors in rats may partially prevent memory impairment induced by MK-801, but not amphetamine- or MK-801-elicited hyperlocomotion.
2015,
Pubmed
Tziortzi,
Imaging dopamine receptors in humans with [11C]-(+)-PHNO: dissection of D3 signal and anatomy.
2011,
Pubmed
Venault,
Benzodiazepine impairs and beta-carboline enhances performance in learning and memory tasks.
,
Pubmed
Visser,
Dose-dependent EEG effects of zolpidem provide evidence for GABA(A) receptor subtype selectivity in vivo.
2003,
Pubmed
Whittington,
Inhibition-based rhythms: experimental and mathematical observations on network dynamics.
2000,
Pubmed
Zanos,
A Negative Allosteric Modulator for α5 Subunit-Containing GABA Receptors Exerts a Rapid and Persistent Antidepressant-Like Action without the Side Effects of the NMDA Receptor Antagonist Ketamine in Mice.
2017,
Pubmed
Zurek,
Sustained increase in α5GABAA receptor function impairs memory after anesthesia.
2014,
Pubmed
